To gain insight into how transcription of the human p53 oncogene is controlled, we characterized the regulatory regions ofthe gene. A 3.8-kilobase-pair (kbp)EcoRI restriction fragment encompassing the 5' end of the human p53 gene, as well as subfragments generated by restriction digests, was cloned upstream of the Escherichia cofl chloramphenicol acetyltransferase (CAT) gene and CAT activity was assayed in extracts of transfected cells. Two ypes of CAT vectors were used: Epstein-Barr virus oriP-derived constructs that were stably introduced into the human cell lines K562, Raji, and HL-60, and pSVO-CAT-derived constructs that were transiently introduced into the monkey cell line COS. By this approach we have identified two promoters for the human p53 gene. One promoter, p53P1, is located 100-250 bp upstream of the 218-bp noncoding first exon; a second, stronger promoter, p53P2, maps within the first introv. CAT activity and expression of CAT RNA indicate that p53P2 functions up to 50-fold more efficiently than p53P1. We conclude that the expression ofthe human p53 gene may be controlled by two promoters and that differential regulation of these promoters may play an important role in the altered expression of the gene in both normal and transformed cells.
The p53 oncogene product, a 53-kDa protein, has been detected at elevated levels in transformed cells of various species, including cells derived from tumor biopsy samples (1) and cells transformed in culture by DNA viruses (2), retroviruses (3) , chemical carcinogens (4) , and x-irradiation (4). In addition, increased expression of p53 can lead to cell immortalization (5) , to increased tumorigenicity of cells (6, 7) , and to transformation of normal primary embryonic rat fibroblasts through cooperation with the activated c-Ha-ras oncogene (5, 8, 9) . p53 may also play a role in the regulation of cell proliferation. p53 expression increases prior to DNA synthesis when resting cells are stimulated to undergo cell division (10, 11) , and inhibition of p53 expression, either by microinjection of anti-p53 monoclonal antibodies (12) or by p53 antisense RNA, inhibits DNA synthesis (13) .
Regulation of p53 expression has been shown to occur at the level of p53 protein stability. In cells transformed by simian virus 40 (SV40), p53 is found in a complex with the SV40 large tumor (T) antigen (2) . This association results in an increase in the stability and steady-state level of p53 (14) . Regulation of p53 expression also occurs at the level of mRNA abundance. After mitogenic stimulation of normal human lymphocytes or murine 3T3 cells, p53 mRNA levels increase 5-and 20-fold, respectively, within 6-14 hr (11, 15) .
Unlike transcription of some other cellular protooncogenes, transcription of the p53 gene has not been shown to be activated in transformed cells by chromosomal translocations, gene amplifications, or retroviral insertions. The possibility exists, therefore, that altered expression of p53 in some transformed cells results from mutations within regulatory regions of the gene or from altered expression of trans-acting factors that are required for appropriate expression of the p53 gene.
To understand how transcription of the p53 gene is regulated, we first located the DNA sequences that mediate expression of the gene, with the aim of understanding their function(s) and of eventually identifying cellular factors that they may bind. Our results indicate that expression of the human gene for p53 may be controlled by two promoters having different strengths. One promoter, designated p53P1, is located 100-250 base pairs (bp) upstream of the 218-bp noncoding first exon (16) . A second promoter, designated p53P2, functions more efficiently and maps within the 5' 1.2 kbp of intron 1. MATERIALS AND METHODS Cell Lines. K562 is a human leukemic cell line derived from a patient with chronic myelogenous leukemia (17) . HL-60 is a human cell line derived from a patient with acute promyelocytic leukemia (18) . Raji is an Epstein-Barr virus (EBV)-genome-positive cell line derived from a Burkitt lymphoma biopsy sample (19) . K562, HL-60, and Raji were grown in RPMI 1640 culture medium containing 10o (vol/vol) fetal bovine serum. COS cells are SV40-transformed monkey fibroblasts (20) and were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.
Recombinant Plasmids. A 3.8-kbp EcoRI restriction fragment containing 2.2 kbp of DNA sequence upstream of the human p53 gene, the 218-bp noncoding first exon, and 1.3 kbp from the 10-kbp first intron was obtained from a A Charon 4A library of genomic DNA isolated from the SV40-transformed human cell line SV80 (21) . The plasmid pSVO-CAT consists of pBR322, the chloramphenicol acetyltransferase (CAT) coding sequences (22) (26) . COS cells at 50-75% confluence in 100-mm culture dishes were transfected with 10 ,ug ofplasmid DNA. Cells were harvested for CAT assays after 72 hr. CAT assays were performed as described (22) . Control experiments indicated that all assays were in the linear range with respect to time and concentration of cell extract.
RNA Analysis. Total cellular RNA was isolated (27) and further purified by sedimentation through 5.7 M CsCl. RNA (20 ,ug) Genetics: Reisman et al. (Fig. 1, Table 1 ).
One explanation for these observations is that cells carrying the p220-CAT construct with p53P2 maintain more copies of the transfected plasmid DNA and that the observed relative increase in CAT activity is a result of gene dosage. To address this question, we measured the number of stably maintained copies of the respective promoters by Southern analysis (29) . Total DNA from K562 cells expressing CAT, either from p53P1 or from p53P2, was digested with restriction enzymes so that the promoter would be released from p220-CAT. The restriction digests released DNA fragments of the expected sizes (Fig. 2) Thus, the increase in CAT activity observed in cells carrying p53P2 cannot be explained by gene dosage and is therefore likely to result from p53P2 being a stronger promoter. p53P2 Maps Within Intron 1. To localize the two p53 promoters, we introduced deletions into the 3.8-kbp DNA fragment with various restriction endonucleases. These derivatives were inserted into the CAT vector pSVO-CAT, and the resulting constructs (Fig. 3) were introduced into COS cells. Cell extracts were prepared and assayed for CAT activity. As shown in Fig. 3 , two promoter activities were also detected in transfected COS cells. Digestion of the 2.4-kbp fragment contained p53P1 activity with HindIII localized p53P1 to within the 350 bp upstream of the Xba I site (Fig. 3e) . Reversing the orientation of either the entire 3.8-kbp fragment (Fig. 3b) or of the sequence containing only p53P1 (Fig. 3d) resulted in no detectable CAT activity. Furthermore, constructs that contained the entire 2.4 kbp upstream of the Xba I site consistently yielded one-half to one-quarter the activity of constructs that contained only the 350 bp containing p53P1 (compare Fig. 3 c and e) . These results indicate that an element that negatively regulates p53P1 may be present upstream of the promoter. As was the case in K562, a second promoter, p53P2, located within the 1.4 kbp downstream of the Xba I restriction site within exon 1, expressed a higher level of CAT activity (Fig. 3f) . To ensure that the observed CAT activity was not somehow due to pBR322 sequences being brought next to p53 sequences, we separated these sequences by reintroducing the 2.4-kbp upstream fragment, which was deleted from this construct, in the inverted orientation. This construct remained competent to express CAT activity (Fig.  3g) . Deletion of the remaining exon 1 sequence by digestion with HindIII did not affect the ability of the remaining 1.2 kbp of intron 1 to promote CAT activity (Fig. 3h) . These results indicate that a promoter is present within the 5' 1.2 kbp of intron 1 of the human p53 gene.
Two Species of CAT RNA Are Present in Cells Expressing CAT from Both p53P1 and p53P2. If both p53 promoters are functional when present together on the 3.8-kbp DNA fragment, then two CAT mRNAs initiating at different sites should be present in the cell. To determine whether this was the case, RNA was extracted from K562-derived cells that carried p220-CAT containing the entire 3.8-kbp fragment. The RNA was subjected to electrophoresis followed by blot hybridization to the 32P-labeled CAT coding sequences. Two CATspecific RNAs, approximately 1.3 and 2.9 kilobases (kb) long, were detected (Fig. 4A) . The presence of two CAT mRNAs is consistent with there being two promoters as indicated by the CAT assays described above. In addition, the difference in the steady-state levels of the two CAT RNAs is consistent with there being two promoters of different strengths. The difference in size of the two CAT mRNAs (=1.6 kb) indicates that p53P2 may lie -1.6 kbp downstream of p53P1, thus locating p53P2 near the 3' end of the 3.8-kbp genomic DNA fragment. To test this, we performed S1 nuclease mapping of the 5' end of mRNA initiating at p53P2. RNA from K562 cells and from K562 cells expressing the CAT gene from the entire 3.8-kbp genomic fragment was hybridized in solution to a 32P-labeled DNA fragment spanning the intron 1 sequences from the end ofthe 3.8-kbp clone and extending 1.2 kbp upstream (Fig. 4B ).
An Si-resistant species of -75 bases was observed only with RNA from K562 cells expressing CAT, indicating that transcripts expressed from p53P2 initiate -75 bp from the end of the DNA fragment (-1.2 kbp downstream of exon 1 ). These CAT-activity 
DISCUSSION
To gain insight into the regulation of the p53 gene, we have begun to locate DNA sequences that control expression of the gene. We constructed recombinant plasmids that contained all or portions of a 3.8-kbp DNA fragment composed of noncoding sequence encompassing the 5' end of the human p53 gene upstream of the CAT gene. These constructs were introduced into cells and assayed for their ability to express the CAT gene. Our results indicate that the human p53 gene contains at least two promoters that are capable of initiating transcription of the CAT gene. p53P1 was described previously (16) and maps to the 250 bp upstream of the first exon. Constructs that contain, in addition to p53P1, sequence upstream of p53P1 yield one-half to one-quarter the CAT activity of constructs containing only p53P1. These results indicate that the sequence upstream of the promoter may contain elements that negatively regulate p53P1. A second promoter, p53P2, is located within intron 1 and is up to 50-fold more efficient than pS3P1 in expressing the CAT gene (Table 1, Fig. 4A ). Transcripts originating from p53P2 were mapped by S1 analysis and found to initiate -1.2 kbp downstream of exon 1 (Fig. 4B) . Sequence upstream of p53P1 may also suppress the expression of p53P2. The CAT activity expressed from constructs containing the entire 3.8-kbp DNA fragment, containing both p53P1 and p53P2, was consistently lower than the CAT activity expressed from constructs containing only p53P2 (Table 1) .
Consistent with the findings presented here, a study by Bienz-Tadmor et al. (30) , comparing the structures of the murine and human p53 regulatory regions, showed that these sequences are highly conserved and that the murine p53 promoter also contains an upstream negative regulatory element. They also identified a highly conserved sequence containing extensive dyad symmetry within exon 1 and suggested that this sequence may play a role in the translation efficiency of the mRNA (30 (33) , is controlled by dual promoters. The c-myc gene is controlled by at least four promoters (34) (35) (36) 
